CytoSorbents Europe GmbH, based in Berlin, is a 100% subsidiary of CytoSorbents Corporation (Princeton, New Jersey, USA) and from Berlin manages sales, marketing and parts of the clinical studies for the product CytoSorb 300 manufactured in Princeton. The company's products are distributed in over 70 countries and are mainly sold to hospitals and contract dealers in the areas of intensive care, cardiac surgery/cardiology and nephrology. In the 2023 financial year the company generated revenues of EUR 26,479,022.68, an increase of 8.0% compared with the previous year, with a product margin of approximately 48%. As of 31 December 2023 the balance sheet total amounted to EUR 59,743,193.40, the deficit not covered by equity amounted to EUR 48,408,821.75 and the annual result was a loss of EUR 7,110,760.43.
Der Import und Export sowie die Vermarktung und der Vertrieb von medizinischen Produkten aller Art und im weitesten Sinne.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Berlin (Charlottenburg) Local Court, HRB 140433 (as of 31 October 2026)
| Name | Type | City |
|---|---|---|
| Phillip Chan | Geschäftsführer(in) | New Jersey/USA |
| Christian Steiner | Geschäftsführer(in) | Berlin |
Source: German Commercial Register (Handelsregister) Berlin (Charlottenburg) Local Court, HRB 140433 (as of 31 October 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2023 | Rohergebnis€14.6M2 | -€7,110,760 | €59,743,193 | — |
| 2022 | Rohergebnis€12.6M2 | -€11,965,351 | €51,598,975 | — |
| 2021 | Rohergebnis€16.2M2 | -€6,185,761 | €41,739,288 | — |
| 2020 | Rohergebnis€16.5M2 | -€2,332,564 | €30,625,726 | — |
| 2019 | Rohergebnis€9.4M2 | -€7,763,890 | €26,219,972 | — |
| 2018 | Rohergebnis€8.1M2 | -€3,149,933 | €16,844,600 | — |
| 2017 | ≤ €12M1 | -€2,722,012 | €12,181,600 | — |
| 2016 | ≤ €12M1 | -€2,108,346 | €8,949,146 | — |
| 2015 | ≤ €12M1 | -€2,656,104 | €6,179,855 | — |
| 2014 | — | -€1,270,401 | €3,226,237 | — |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
2 Rohergebnis nach § 276 HGB: Umsatzerlöse abzüglich Materialaufwand bzw. Herstellungskosten. Kleine und mittelgroße Kapitalgesellschaften dürfen diese Posten zusammenfassen; die Umsatzerlöse selbst sind dann nicht veröffentlicht und liegen über dem Rohergebnis.
Sign in to download data
Source: German Commercial Register (Handelsregister) Berlin (Charlottenburg) Local Court, HRB 140433 (as of 31 October 2026)
Menicon Gesellschaft mit beschränkter Haftung
Offenbach am Main · Einzelhandel mit Brillen und Kontaktlinsen
NuVasive Germany GmbH
Bremen · Einzelhandel mit sonstigen medizinischen und orthopädischen Artikeln
Cook Deutschland GmbH
Mönchengladbach · Einzelhandel mit sonstigen medizinischen und orthopädischen Artikeln
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €12,100,280 | 95.7% |
| Depreciation | €130,357 | 1.0% |
| Interest & Similar | €418,960 | 3.3% |
